compounded semaglutide fda warning letter compounding news Navigating Semaglutide: What Health Care Providers Need to Know FDA Issues Warning Letters to – Compounded Semaglutide Manufacturing Ban

DOI:10.1161/CIRCULATIONAHA.122.059595 Las estrategias intensivas para reducir la glucosa no lograron reducir efectivamente la morbilidad y la mortalidad cardiovasculares en pacientes con diabetes con alto riesgo cardiovascular y la visin actuar para reducir riesgo cardiovascular es un abordaje intensivo y transdiciplinario de los factores de riesgo cardiovascular y la utilizacin de frmacos cardiometablicos con demostrado beneficio en reduccin de eventos cardiovascular (MACE: Infarto no fatal, ACV no falla, muerte cardiovascular) y proteccin cardiorrenal (#SGLT2i #GLP1ar)

They suggested that the higher rate of hair-loss in patients taking GLP-1s could be attributed to rapid weight loss, which is known to trigger hair shedding

Loperamide: For diarrhoea, loperamide is an alternative to Pepto-Bismol

Think you may need a vegan B12 supplement